{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:44:33Z","timestamp":1786221873759,"version":"build-2736575974"},"reference-count":95,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005318"],"award-info":[{"award-number":["INV-005318"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U01AI139547"],"award-info":[{"award-number":["U01AI139547"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.028","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T21:32:05Z","timestamp":1676842325000},"page":"1799-1807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Meeting Summary: Global Vaccine and Immunization Research Forum, 2021"],"prefix":"10.1016","volume":"41","author":[{"given":"Andrew","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-3509","authenticated-orcid":false,"given":"Angela","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie X.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahida","family":"Baqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Touchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Earle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Fenton","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.02.028_b0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1377\/hlthaff.2020.00103","article-title":"Return on Investment from Immunization Against 10 Pathogens In 94 Low- and Middle-Income Countries, 2011\u201330","volume":"39","author":"Sim","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.vaccine.2023.02.028_b0010","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1377\/hlthaff.2017.0861","article-title":"The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries","volume":"37","author":"Chang","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.vaccine.2023.02.028_b0015","unstructured":"Immunization Agenda 2030. Immunization Agenda 2030: A global strategy to leave no one behind. 2021. https:\/\/www.immunizationagenda2030.org\/ [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0020","unstructured":"Vanderslott S, Dadonaite B, Roser M. Vaccination. OurWorldinData.org, 2013. Graphic courtesy of Melanie Saville of the Coalition for Epidemic Preparedness Innovations. https:\/\/ourworldindata.org\/vaccination."},{"key":"10.1016\/j.vaccine.2023.02.028_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110143","article-title":"SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity","volume":"37","author":"Joyce","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.02.028_b0030","unstructured":"Rogers J. Going universal: The search for an all-in-one coronavirus vaccine. Coalition for Epidemic Preparedness Innovations, 2021. https:\/\/cepi.net\/news_cepi\/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine\/ [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020368118","article-title":"Vaccinology in the post-COVID-19 era","volume":"118","author":"Rappuoli","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.02.028_b0040","unstructured":"World Health Organization. Overview of the types\/classes of candidate vaccines against MERS-CoV. 2021. https:\/\/www.who.int\/publications\/m\/item\/overview-of-the-types-classes-of-candidate-vaccines-against-mers-cov [accessed September 22, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.02.028_b0050","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.02.028_b0055","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.02.028_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633776","article-title":"A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.vaccine.2023.02.028_b0065","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1080\/21645515.2021.1911204","article-title":"COVID-19 vaccine platforms: Delivering on a promise?","volume":"17","author":"Verdecia","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.02.028_b0070","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMcibr2111445","article-title":"In Gratitude for mRNA Vaccines","volume":"385","author":"Stuart","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0075","unstructured":"Zimmer C, Corum J, Wee S-L. Coronavirus Vaccine Tracker. New York Times, 2021. https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html [accessed March 19, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.02.028_b0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.02.028_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0095","article-title":"Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Frontiers in Medical","volume":"2","author":"Xu","year":"2020","journal-title":"Technology"},{"key":"10.1016\/j.vaccine.2023.02.028_b0100","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.02.028_b0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/epirev\/mxz012","article-title":"CEPI: Driving Progress Toward Epidemic Preparedness and Response","volume":"41","author":"Gouglas","year":"2019","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2023.02.028_b0110","unstructured":"Coalition for Epidemic Preparedness Innovations. Our Portfolio. https:\/\/cepi.net\/research_dev\/our-portfolio\/ [accessed November 12, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0115","unstructured":"World Health Organization. An R&D Blueprint for Action to Prevent Epidemics, Update 2017. 2017. https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/an-randd-blueprint-for-action-to-prevent-epidemics-update-2017.pdf [accessed January 1, 2023]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0120","unstructured":"World Health Organization. COVID-19 Research and Innovation Achievements. 2021. https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/r-d-blueprint-meetings\/r-d-achievements-report_v42.pdf [accessed November 12, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0125","unstructured":"COVAX. COVAX Global Supply Forecast. 2021. https:\/\/www.gavi.org\/sites\/default\/files\/covid\/covax\/COVAX-Supply-Forecast.pdf [accessed January 5, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0130","unstructured":"Pandemic Preparedness Partnership. 100 Days Mission to Respond to Future Pandemic Threats: Reducing the impact of future pandemics by making Diagnostics, Therapeutics and Vaccines available within 100 Days. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/992762\/100_Days_Mission_to_respond_to_future_pandemic_threats__3_.pdf [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0135","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1172\/JCI139601","article-title":"Prototype pathogen approach for pandemic preparedness: world on fire","volume":"130","author":"Graham","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.02.028_b0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic","volume":"19","author":"Graham","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2023.02.028_b0145","unstructured":"Division of Research, Innovation, and Ventures: Revolutionize the Way We Prevent, Detect, and Respond to Major 21st Century Health Security Threats. U.S. Department of Health & Human Services, Biomedical Advanced Research and Development Authority. https:\/\/drive.hhs.gov\/index.html [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0150","unstructured":"World Health Organization. Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing: Expression of interest. 2021. https:\/\/www.who.int\/news-room\/articles-detail\/establishment-of-a-covid-19-mrna-vaccine-technology-transfer-hub-to-scale-up-global-manufacturing [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0155","unstructured":"Our World in Data. COVID-19 vaccine doses administered per 100 people, by income group. https:\/\/ourworldindata.org\/grapher\/cumulative-covid-vaccinations-income-group?country=High+income\u223cLow+income\u223cLower+middle+income\u223cUpper+middle+income [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0160","unstructured":"Batavia Biosciences. HIP-Vax: low-cost vaccine manufacturing. www.bataviabiosciences.com\/viral-vaccines\/technologies\/hip-vax-vaccine-manufacturing\/ [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0165","unstructured":"World Health Organization. New consortium working to boost vaccine production in South Africa. MPP, WHO, AFRIGEN, BIOVAC, SAMRC, and Africa CDC sign a letter of intent towards establishing the tech transfer hub in South Africa. Geneva.2021. https:\/\/www.who.int\/news\/item\/30-07-2021-new-consortium-working-to-boost-vaccine-production-in-south-africa [accessed January 1, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0170","unstructured":"Pan American Health Organization. PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines. 2021. https:\/\/www.paho.org\/en\/news\/21-9-2021-paho-selects-centers-argentina-brazil-develop-covid-19-mrna-vaccines [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0175","unstructured":"US Department of Health & Human Services. BARDA establishes four new partnerships to explore innovative vaccine delivery technologies. 2020. https:\/\/www.medicalcountermeasures.gov\/newsroom\/2020\/barda-new-partnerships\/ [accessed January 3, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0180","article-title":"Covid-19 vaccine patch outshines injectable jab in pre-clinical study","author":"Parkins","year":"2021","journal-title":"Clinical Trials Arena"},{"key":"10.1016\/j.vaccine.2023.02.028_b0185","unstructured":"Integrated Project Services. Blow-Fill-Seal & Prefilled Syringes: A Solution for Complex Formulations. https:\/\/www.ipsdb.com\/happenings\/insights\/blow-fill-seal-prefilled-syringes-a-solution-for-complex-formulations [accessed January 3, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0190","unstructured":"Downham M, Hesselink R. Multidose Prefilled Pouches for Pandemics. 2021. https:\/\/www.dcvmn.org\/IMG\/pdf\/dcvmn_webinar_the_multidose_prefilled_bags_for_pandemics_08apr21.pdf [accessed January 3, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0195","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1016\/j.vaccine.2021.05.102","article-title":"A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy","volume":"39","author":"Kristensen","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0200","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1016\/j.vaccine.2021.07.091","article-title":"Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries","volume":"39","author":"Giersing","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0205","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1016\/j.vaccine.2021.08.024","article-title":"Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations","volume":"39","author":"Mvundura","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0210","unstructured":"von der Leyen U, Ghebreyesus TA. A global pandemic requires a world effort to end it - none of us will be safe until everyone is safe. The Telegraph.2020. https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/global-pandemic-requires-world-effort-end-none-us-will-safe\/ [accessed February 2, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101429","article-title":"Human challenge trials in vaccine development","volume":"50","author":"Sekhar","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2023.02.028_b0220","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202103-0620OC","article-title":"Innate-like Gene Expression of Lung-resident Memory CD8+ T-cells During Experimental Human Influenza: A Clinical Study","author":"Paterson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0225","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bioe.12802","article-title":"Ethical issues surrounding controlled human infection challenge studies in endemic low-and middle-income countries","volume":"34","author":"Jamrozik","year":"2020","journal-title":"Bioethics"},{"key":"10.1016\/j.vaccine.2023.02.028_b0230","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s13063-021-05455-7","article-title":"Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders","volume":"22","author":"Chi","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2023.02.028_b0235","first-page":"6","article-title":"Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection. JCI","author":"Kapulu","year":"2021","journal-title":"Insight"},{"key":"10.1016\/j.vaccine.2023.02.028_b0240","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMp2106970","article-title":"SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic","volume":"385","author":"Rapeport","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0245","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.vaccine.2020.10.075","article-title":"Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group","volume":"39","author":"Jamrozik","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0250","first-page":"1105","article-title":"BCG Specific and Nonspecific Effects: Different Questions","volume":"224","author":"Prentice","year":"2021","journal-title":"Similar Challenges J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.028_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681449","article-title":"Aging and Options to Halt Declining Immunity to Virus Infections","volume":"12","author":"Palacios-Pedrero","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.02.028_b0260","unstructured":"World Health Organization. Global Tuberculosis Report. 2022. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1474924\/retrieve [accessed January 1, 2023]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0265","unstructured":"World Health Organization. Global Tuberculosis Report. 2021. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1379788\/retrieve [accessed December 28, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0270","doi-asserted-by":"crossref","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","article-title":"Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study","volume":"8","author":"Hogan","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.02.028_b0275","doi-asserted-by":"crossref","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73:e2005-e15. DOI: 10.1093\/cid\/ciaa1198.","DOI":"10.1093\/cid\/ciaa1198"},{"key":"10.1016\/j.vaccine.2023.02.028_b0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4: IC31 Vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0285","unstructured":"Bill & Melinda Gates Medical Research Institute. BCG Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04152161 [accessed December 28, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0290","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0295","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b Controlled Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0300","unstructured":"Bill & Melinda Gates Medical Research Institute. Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72\/AS01E in Participants With Well-controlled HIV (MESA-TB). 2021. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04556981 [accessed December 28, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0305","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","volume":"384","author":"Gray","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0310","unstructured":"Janssen Vaccines & Prevention B.V. A Study to Assess the Efficacy of a Heterologous Prime\/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03060629 [accessed December 28, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0315","unstructured":"International AIDS Vaccine Initiative. IAVI statement on results from Phase IIb Imbokodo HIV vaccine clinical trial. https:\/\/www.iavi.org\/news-resources\/features\/iavi-statement-on-results-from-phase-iib-imbokodo-hiv-vaccine-clinical-trial [accessed December 28, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0320","unstructured":"Janssen Vaccines & Prevention B.V. A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and\/or Transgender Individuals (MOSAICO). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03964415 [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0325","unstructured":"International AIDS Vaccine Initiative. A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03547245 [accessed February 7, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0330","unstructured":"International AIDS Vaccine Initiative, Scripps Research. Fact sheet: Understanding the results from IAVI G001 presented at HIV R4P \/ Virtual 2021. https:\/\/www.iavi.org\/images\/phocadownload\/IAVI-G001-Fact-Sheet.pdf [accessed February 7, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0335","unstructured":"International AIDS Vaccine Initiative. A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03699241 [accessed February 7, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0340","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.028_b0345","unstructured":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2021 - conclusions and recommendations. Wkly Epidemiol Rec. 2021;96:613-32, https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/350649\/WER9650-eng-fre.pdf [accessed December 31, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0350","unstructured":"World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk: Historic RTS,S\/AS01 recommendation can reinvigorate the fight against malaria. 2021. https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk [accessed February 7, 2022]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0355","unstructured":"World Health Organization (WHO). WHO Preferred Product Characteristics for Next Generation Influenza Vaccines. 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/258767\/9789241512466-eng.pdf [accessed December 31, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0360","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2023.02.028_b0365","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2023.02.028_b0370","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0375","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.028_b0380","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2023.02.028_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106403","article-title":"Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals","volume":"105","author":"Teppler","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.vaccine.2023.02.028_b0390","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s13063-021-05608-8","article-title":"Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial","volume":"22","author":"Barnabas","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2023.02.028_b0395","unstructured":"World Health Organization. Recommendation for an Emergency Use Listing (EUL) of Novel Oral Polio Vaccine Type 2 (nOPV2) Submitted by PT Biofarma (Persero). 2020. https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/nOPV2_EUL_recommendation.pdf [accessed December 27, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0400","first-page":"1","article-title":"A comprehensive and critical overview of schistosomiasis vaccine candidates","author":"Al-Naseri","year":"2021","journal-title":"J Parasit Dis"},{"key":"10.1016\/j.vaccine.2023.02.028_b0405","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12929-020-0621-y","article-title":"Schistosomiasis vaccine development: update on human clinical trials","volume":"27","author":"Molehin","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2023.02.028_b0410","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jam.15055","article-title":"Advances in the development of Salmonella-based vaccine strategies for protection against Salmonellosis in humans","volume":"131","author":"Sears","year":"2021","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2023.02.028_b0415","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jinf.2021.06.029","article-title":"Incidence of non-typhoidal Salmonella invasive disease: A systematic review and meta-analysis","volume":"83","author":"Marchello","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.02.028_b0420","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/polysaccharides2030042","article-title":"Polysaccharide Vaccines: A Perspective on Non-Typhoidal Salmonella","volume":"2","author":"Perera","year":"2021","journal-title":"Polysaccharides"},{"key":"10.1016\/j.vaccine.2023.02.028_b0425","unstructured":"World Health Organization (WHO). Comparison table of WHO prequalified typhoid conjugate vaccines (TCVs). 2021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/345367\/WHO-IVB-2021.04-eng.pdf [accessed December 31, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0430","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/21645515.2018.1522468","article-title":"Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness","volume":"15","author":"Larson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.02.028_b0435","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1529100618760521","article-title":"Increasing Vaccination: Putting Psychological Science Into Action","volume":"18","author":"Brewer","year":"2017","journal-title":"Psychol Sci Public Interest"},{"key":"10.1016\/j.vaccine.2023.02.028_b0440","unstructured":"World Health Organization, UNICEF. Data for action: achieving high uptake of COVID-19 vaccines: Interim guidance. 2021. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1341480\/retrieve [accessed December 27, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0445","unstructured":"Access to Medicine Foundation. Access to Medicine Index 2021. https:\/\/accesstomedicinefoundation.org\/medialibrary\/resources\/613f5fb390319_Access_to_Medicine_Index_2021.pdf [accessed January 1, 2023]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0450","unstructured":"Coalition for Epidemic Preparedness Innovations (CEPI). CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019. https:\/\/cepi.net\/news_cepi\/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019\/ [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0455","unstructured":"World Health Organization. Emergency Use Listing Procedure. 2022. https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/eulprocedure.pdf [accessed January 1, 2023]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0460","unstructured":"World Health Organization, International Coalition of Medicines Regulatory Authorities (ICMRA). Deep dive report on the review of provisions and procedures for emergency authorization of medical products for COVID-19 among ICMRA members - July 2021. 2021. https:\/\/www.icmra.info\/drupal\/sites\/default\/files\/2021-12\/eua_deep_dive_report.pdf [accessed December 30, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0465","unstructured":"World Health Organization Strategic Advisory Group of Experts on Immunization. The Global Vaccine Action Plan 2011-2020 Review and Lessons Learned. WHO Press, 2019. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1255869\/retrieve [accessed December 27, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0470","unstructured":"Immunization Agenda 2030. SP7 Research and Innovation. 2021. https:\/\/www.immunizationagenda2030.org\/images\/documents\/BLS20116_IA_Global_strategy_document_SP_7_002.pdf [accessed December 27, 2021]."},{"key":"10.1016\/j.vaccine.2023.02.028_b0475","unstructured":"World Health Organization. Progress and Challenges with Achieving Universal Immunization Coverage. 2022. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/wuenic-progress-and-challenges-15-july-2022.pdf [accessed January 1, 2023]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:21:23Z","timestamp":1786220483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001639"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting Summary: Global Vaccine and Immunization Research Forum, 2021","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}